BACKGROUND: Aromatase inhibitors (AIs) may cause a rise in estrogen levels due to ovarian function recovery in women with clinical chemotherapy-induced ovarian failure (CIOF). We carried out a prospective registry trial to identify predictors of ovarian function recovery during AI therapy. PATIENTS AND METHODS: Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole. Subjects underwent frequent assessment using an ultrasensitive estradiol assay. Multivariable analysis was used to evaluate clinical and biochemical predictors of ovarian function recovery within 48 weeks. RESULTS: Recovery of ovarian function during AI therapy was observed in 13 of 45 (28.9%) assessable subjects after a median 2.1 months (range 0.6-11.9). Median age at chemotherapy initiation was statistically significantly different between those who regained ovarian function (43 years, range 40-51) and those who remained postmenopausal (49 years, range 44-52; P < 0.0001). CONCLUSIONS: A significant proportion of women with CIOF recover ovarian function during AI therapy, including a woman over age 50 at initiation of chemotherapy. Tamoxifen remains the standard of care for women with CIOF. If an AI is used, patients should be monitored frequently with high-quality estradiol assays. CLINICALTRIALS.GOV: NCT00555477.
BACKGROUND: Aromatase inhibitors (AIs) may cause a rise in estrogen levels due to ovarian function recovery in women with clinical chemotherapy-induced ovarian failure (CIOF). We carried out a prospective registry trial to identify predictors of ovarian function recovery during AI therapy. PATIENTS AND METHODS: Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole. Subjects underwent frequent assessment using an ultrasensitive estradiol assay. Multivariable analysis was used to evaluate clinical and biochemical predictors of ovarian function recovery within 48 weeks. RESULTS: Recovery of ovarian function during AI therapy was observed in 13 of 45 (28.9%) assessable subjects after a median 2.1 months (range 0.6-11.9). Median age at chemotherapy initiation was statistically significantly different between those who regained ovarian function (43 years, range 40-51) and those who remained postmenopausal (49 years, range 44-52; P < 0.0001). CONCLUSIONS: A significant proportion of women with CIOF recover ovarian function during AI therapy, including a woman over age 50 at initiation of chemotherapy. Tamoxifen remains the standard of care for women with CIOF. If an AI is used, patients should be monitored frequently with high-quality estradiol assays. CLINICALTRIALS.GOV: NCT00555477.
Entities:
Keywords:
aromatase inhibitor; breast cancer; chemotherapy-induced ovarian failure; estradiol; ovarian function
Authors: Ian E Smith; Mitch Dowsett; Yoon-Sim Yap; Geraldine Walsh; Per E Lønning; Richard J Santen; Daniel Hayes Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: MaryFran R Sowers; Aimee D Eyvazzadeh; Daniel McConnell; Matheos Yosef; Mary L Jannausch; Daowen Zhang; Sioban Harlow; John F Randolph Journal: J Clin Endocrinol Metab Date: 2008-07-01 Impact factor: 5.958
Authors: Jeanne A Petrek; Michelle J Naughton; L Douglas Case; Electra D Paskett; Elizabeth Z Naftalis; S Eva Singletary; Paniti Sukumvanich Journal: J Clin Oncol Date: 2006-02-13 Impact factor: 44.544
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Cesar A Santa-Maria; Amanda Blackford; Anne T Nguyen; Todd C Skaar; Santosh Philips; Steffi Oesterreich; James M Rae; Zeruesenay Desta; Jason Robarge; Norah Lynn Henry; Anna M Storniolo; Daniel F Hayes; Roger S Blumenthal; Pamela Ouyang; Wendy S Post; David A Flockhart; Vered Stearns Journal: Clin Cancer Res Date: 2015-10-13 Impact factor: 12.531
Authors: Meritxell Bellet; Kathryn P Gray; Prudence A Francis; István Láng; Eva Ciruelos; Ana Lluch; Miguel Angel Climent; Gustavo Catalán; Antoni Avella; Uriel Bohn; Antonio González-Martin; Roser Ferrer; Roberto Catalán; Analía Azaro; Agnita Rajasekaran; Josefa Morales; Josep Vázquez; Gini F Fleming; Karen N Price; Meredith M Regan Journal: J Clin Oncol Date: 2016-01-04 Impact factor: 44.544
Authors: Kathryn J Ruddy; Anne O'Neill; Kathy D Miller; Bryan P Schneider; Emily Baker; Joseph A Sparano; Chau Dang; Donald W Northfelt; George W Sledge; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2014-03-02 Impact factor: 4.872
Authors: Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry Journal: Breast Cancer Res Treat Date: 2016-12-09 Impact factor: 4.872